The lead specimen treats a decade of insider critique as a correction that should have weakened RCTs. Deaton and Pritchett named external validity. The field kept running trials.
That is also what a field does when it reads the critique as a limit of the best tool it has, not as a kill. Component 6 is supposed to be what makes the test falsifiable. If "people published objections and the method continued" is enough, every living empirical method is a reward substrate.
The missing cut is whether a rival answer to "what works" lost on the merits, or never had a lab.
Narrower than a kill. The critics were senior people writing in the field's own journals, and they had no competing hiring or funding pipeline.
A limit that leaves the method usable will not grow a second lab by itself. The RCT row then shows a winner without a staffed alternative. That is common. It is not a frame that outlived a result that made it unusable.
Then component 6 is scoring "was there a second lab," not "did the frame stay false."
Those come apart. No second lab will be true of most winners. Persistence past a result that made the method unusable is rare. The RCT writeup cites the first and talks like the second.
Pick one thing you can actually watch.
J-PAL in 2003, Deaton in 2010, the Nobel in 2019. If component 6 is "no rival hiring channel," the Nobel is not persistence past correction. It is the same channel still paying.
What would make 6 fail on this row: after 2010, development groups that still like identification but stop using RCT experience as the hiring filter. If that mixed pattern exists, "the documentation did not change the equilibrium" is too coarse for the specimen the essay hangs on.
The ex-ante rule is supposed to stop you from reading the gradient off the win. The gradient named here is top-journal taste for clean identification in the early 1990s — Card, Krueger, Angrist, Imbens — before development RCTs took over.
That is a larger family. If identification already paid, RCT dominance is a specialization inside a gradient that was not in doubt. The rule then does not protect the specimen. It moves the circle out to "causal papers pay."
Split those.
"Identification pays" is Card and Krueger. "RCT is how you answer what works in development" is J-PAL. The second is the thing the essay is diagnosing.
If early-1990s journals would have taken a structural development paper that actually identified a mechanism, the RCT-as-the-field's-answer story is not yet the 1990s gradient. The page needs a reject of that class, or the ex-ante sentence is a family resemblance.
"The response was more RCTs, meta-RCTs, and refinements" is also what a method looks like when it is still in use and people are patching a known hole.
A method that answers a limitation with more of itself is either swallowing the counter or still being the tool. Component 6 does not say which, except by a sense that this one should have shrunk.